Positions

  • Present 2009

    Director

    ScienceHA, Inc

  • Present 2010

    Adjunct Faculty

    University of Toronto, Faculty of Medicine, Toronto, Canada

  • 2009 2006

    Research Scientist

    Mount Sinai Hospital/Lunenfeld Research Institute, Toronto, Canada

  • 2006 2001

    Research Scientist

    University Health Network/Ontario Cancer Institute, Toronto, Canada

  • 1995 1991

    Clinical Chemistry Laboratory Scientist

    Huddinge University Hospital, Stockholm, Sweden

Education

  • PMP 2012

    Project Management Professional

    Project Management Institute

  • Ph.D.2001

    Ph.D. in Medical Genetics

    Karolinska Institute, Stockholm, Sweden

  • MSc.1996

    Master of Molecular Biology

    Uppsala University, Uppsala, Sweden

  • B.Sc. 1990

    Bachleor of Clinical Chemistry

    University College of Health Sciences, Stockholm, Sweden

Research Projects

  • image

    Reprofiling and Repurposing FDA-Approved-Drugs

    In this project a genome- and gene-expression-based proprietary approach were used to select specific drug combinations based on their known pharmacological mechanism. The drug reprofiling strategy (also called repurposing, repositioning, or retasking) was then used to reinvestigate drug candidates that have been successfully used in other indication for potential new therapeutic applications in cancer therapy. Several drug combinations have been identified with cytotoxic effects on cancer cells with specific phenotype. These drug combinations are under further investigation and additional testing.

  • image

    Novel Axin2 (Conductin) Interacting Partners

    One of the most reliable approaches for determining the novel function of a given protein is to see if it is interacting with another protein with a known function. Our approach is based on isolating Axin protein assemblies and characterising the components by mass spectrometry (MS). We are also exploring how distruption in these novel Axin-protein complexes lead to human diseases.

  • image

    Molecular Study of Axin in Normal and Cancer Cells

    Axins (Axin1 and Axin2) are negative regulator of the Wnt signaling pathway as their over-expression results in beta-catenin down-regulation. Axin is able to bring beta-catenin and GSK3s into close proximity, thus facilitating beta-catenin phosphorylation. A variety of in vitro and in vivo studies, suggest that Axin serves as a scaffold protein that binds directly many proteins involved in Wnt signaling pathway. Axin contains several domains that mediate direct binding to APC, GSK3s (GSK3a and GSK3b), beta-catenin, Dishevelled, PP2A, CK1, MEEK1, as well as Axin itself. Deregulation of both Axin1 and Axin2 have been found in different forms of cancer (Sima Salahshor and James R Woodgett). The aim of this project is to explore how Axin deregulation contributes to carcinogenesis.

    Reference: Sima Salahshor and James R Woodgett. The links between Axin and carcinogenesis. Journal of Clinical Pathology (2005); Mar; 58:225-236. [pdf]

  • image

    Abnormal Wnt Signaling in Pancreas Cancer

    In addition to colorectal cancer, we are investigating whether/how defect(s) in Wnt signal transduction contributes to pancreas and esophageal cancer initiation and/or progression. After pancreas cancer, esophageal cancer is the most fatal type of cancer. So far very few genetics abnormalies have been directly linked to this type of disease. Recently, in collaboration with scientists at the Nelson Mandela School of Medicine in South Africa, Ontario Cancer Institute (OCI)/Princess Margaret Hospital (PMH) and the Samuel Lunenfeld Research Institute (SLRI)/ Mount Sinai Hospital (MSH) in Canada, we have shown that many components of the Wnt signal transduction pathway are deregulated in esophageal squamous cell carcinomas. In addition, we have been able to identify a specific type of E-cadherin abnormality that occurs more frequently in esophageal tumors (Sima Salahshor et al, 2008).

    References:

    Stefano Serra, Sima Salahshor, Mosa Fagih, Firouzeh Niakosari, Jasim M Radhi, Runjan Chetty. Nuclear Expression of E-Cadherin in Solid Pseudopapillary Tumors of the Pancreas. Journal of Pancreas (2007); 8(3):296-303.

    Runjan Chetty, Stefano Serra, Sima Salahshor, Khaled Alsaad, Warren Shih, Hagen Blaszyk, James R Woodgett, Ming-Sound Tsao. Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. Human Pathology (2006); 37:212-217.

    Runjan Chetty, Sima Salahshor, B Bapat, Terri Berk, M Croitoru, Steven Gallinger. Intraductal papillary mucinous neoplasm of pancreas in a patient with attenuated familial adenomatous polyposis. Journal of Clinical Patholgy. (2005); 58(1):97-101.

  • image

    E-cadherin (CDH1) Role in Cancer Initiation and Progression

    We have recently identified a specific type of E-cadherin abnormality that occurs more frequently in esophageal tumors (Sima Salahshor et al, 2008). E-cadherin plays a crucial role in epithelial cell-cell adhesion and in the maintenance of tissue architecture. Loss of E-cadherin is believed to be an early step in metastatic dissemination. In esophageal cancer, the liver, lung and the bones are the most common sites of metastases. Metastasis is responsible for 90% of the deaths caused by cancer. Learning how E-cadherin funcation will increase our understanding of what triggers cancer cells to start the complicated process of metastasis, and will result in the generation of novel targets for therapies to aid in the prevention of metastasis.

    References:

    Runjan Chetty, Stefano Serra, Sima Salahshor. E-cadherin in solid pseudopapillary tumors of the pancreas. Human Pathology (2008) Sep;39(9):1407-8.

    Runjan Chetty, Stefano Serra, Sima Salahshor. Nuclear Expression of E-cadherin. Am J Surg Pathol (2008) Aug;32(8):1269-70.

    Stefano Serra, Sima Salahshor, Mosa Fagih, Firouzeh Niakosari, Jasim M Radhi, Runjan Chetty. Nuclear Expression of E-Cadherin in Solid Pseudopapillary Tumors of the Pancreas. Journal of Pancreas (2007); 8(3):296-303.

    Sima Salahshor, Richard Naido, Stefano Serra, Warren Shih, Ming-Sound Tsao, Runjan Chetty, James R Woodgett. Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Modern Pathology (2008) Mar;21(3):271-81. Epub 2007 Dec 14. [pdf]

    Sima Salahshor , Huagang Huo , Chieu B. Diep, Anu Loukola, Hong Zhang, Tao Liu, Jindong Chen, Lennart Iselius, Carlos Rubio, Ragnhild A. Lothe, Lauri Aaltonen, Xiao-Feng Su, Gudrun Lindmark, Annika Lindblom. A germline E-cadherin mutation in a family with gastric and colon cancer. International Journal of Molecular Medicine. (2001); 8(4):439-43.

    Sima Salahshor , Huagang Huo, Vessela N. Kristensen, Niklas Loman, Sara Sjöberg-Margolin, Anne-Lise Borresen-Dale, Åke Borg, Annika Lindblom. Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Research (2001); 3:199-207.

  • image

    Biomarker Discovery for Early Detection of Colorectal Cancer

    Identification of gene products whose abnormal expression can be detected at early stage of tumor progression could improve the therapeutic index for tumor therapy. Using cDNA microarrays comprising 19,200 human genes (www.microarrays.ca), we have examined the gene expression profile of adenomas and corresponding normal tissues obtained from patients with familial adenomatous polyposis (FAP). Statistical analysis using SAM and GeneTraffic revealed eighty four transcripts to be represented at statistically significant different levels in all adenomas compared to normal tissues (p< 0.05).

    Pregnancy specific beta-1 glycoprotein 9 (PSG9) was the most statistically significant candidate in these experiments and therefore was selected for further analysis (Sima Salahshor et al, 2005). This project was originally conducted in collaboration with scientists at Princess Margaret Hospital (PMH) and Mount Sinai Hospital (MSH).

    Detailed molecular study of PSG9, as well as other identified tumor markers will help us to develop more accurate method(s) to detect, diagnose, and monitor cancer.

    The abnormal expression of the other identified colorectal cancer biomarkers have also been verified in a series of primary tumors. Interestingly, abnormal expression of some of these early markers can also be detected in tumor metastasis.

    References:

    Sima Salahshor, Jason Goncalves, Runjan Chetty, Steven Gallinger, James R Woodgett. Differential gene expression profile reveals deregulation of pregnancy specific b 1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer (2005); 5:66.

    Helene Fischer, Sima Salahshor, Roger Stenling, Jan Björk, Gudrun Lindmark, Lennart Iselius, Carlos Rubio, Annika Lindblom. COL11A1 in FAP polyps and in sporadic colorectal tumors. BMC Cancer (2001); 1(1):17.

  • image

    Microsatellite Instability (MIN) and Chromosomal Instability (CIN) in Cancer

    Chromosomal instability (CIN) includes alterations in chromosome number, chromosome translocation and gene amplification. Microsatellite instability (MSI) refers to mutations in short motifs of tandemly repeated nucleotides resulting from replication errors and deficient mismatch repair (MMR). Most sporadic colorectal cancer show chromosomal instability, while hereditary colorectal cancer (or HNPCC) exhibit microsatellite instability.

    References:

    Sima Salahshor , Konrad Koelble, Carlos Rubio, Annika Lindblom. Microsatellite instability and hMLH1, hMSH2 protein expression in familial and sporadic colorectal cancer. Laboratory Investigation (2001); 81: 535-541.

    Tao Liu, Jindong Chen, Sima Salahshor, Ewa Holmberg, Henrik Grönberg, Annika Lindblom. Screening families with endometrial and colorectal cancers for germline mutations. Journal of Medical Genetics (2001); 38(9):E29.

    Sima Salahshor , Ulf Kressner, Helene Fischer, Gudrun Lindmark, Lars Påhlman, Bengt Glimelius, Annika Lindblom. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. British Journal of Cancer (1999); 81(2):190-3.

    Sima Salahshor , Ulf Kressner, Lars Påhlman, Bengt Glimelius, Gudrun Lindmark, Annika Lindblom. Colorectal cancer with and without microsatellite instability involves different genes. Genes, Chromosomes and Cancer (1999); 26:247-252.

Filter by type:

Sort by year:

Changing Paradigms in Prostate Cancer Treatment

Sima Salahshor
Seminar Presentation Presentation, April 18, 2013

The Signaling Pathways of Cancer | Transduction Pathways in Normal and Diseased Tissues

Sima Salahshor, Department of Laboratory of Medicine, Faculty of Medicine, University of Toronto
Lecture Presentation February 13, 2013

Picturing Science: An overview of Imaging Technologies

Sima Salahshor, Department of Laboratory of Medicine, Faculty of Medicine, University of Toronto
Lecture PresentationJanuary 8, 2013

E-cadherin in solid pseudopapillary tumors of the pancreas

Runjan Chetty, Stefano Serra, Sima Salahshor, Human Pathology (2008) Sep; 39 (9): 1407
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/18706351

Nuclear Expression of E-cadherin

Runjan Chetty, Stefano Serra, Sima Salahshor, American Journal of Surgical Pathology (2008) Jun 27.
Journal Paperhttp://www.ncbi.nlm.nih.gov/pubmed/18594465

Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas

Sima Salahshor, Richard Naido, Stefano Serra, Warren Shib, Ming-Sound Tsao, Runjan Chetty, James R. Woodgett, Modern Pathology (2008) Mar;21(3):271-81.
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/18084253

Analysis of novel Axin2 variants in colorectal cancer

Sima Salahshor and James R Woodgett, 9th Annual Meeting of American Association of Cancer Research, San Diego, USA
Poster Presentation PDF

Nuclear expression of E-cadherin in Solid Pseudo papillary tumors

Stefano Serra, Sima Salahshor, Mosa Fagih, Firouzeh Niakosari, Jasim M Radhi, Runjan Chetty, Journal of Pancreas (2007) May 9;8(3):296-303.
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/17495358

Expression of Wnt signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: A tissue microarray analysis

Runjan Chetty, Stefano Serra, Sima Salahshor, Khaled Alsaad, Warren Shib, Hagen Blaszyk, James R Woodgett, Ming-Sound Tsao, Human Pathology (2006) 37:212-217.
Journal Paperhttp://www.ncbi.nlm.nih.gov/pubmed/16426922

Pregnancy Specific 1 Glycoprotein 9 (PSG9) in Human Cancer

Sima Salahshor and James R Woodgett, Conference in cell signaling in normal and cancer cells, Banff, Canada, May 2006
Poster Presentation PDF

Differential gene expression profile reveals deregulation of pregnancy specific beta-1 glycoprotein 9 early during colorectal carcinogenesis

Sima Salahshor, Jason Goncalves, Runjan Chetty, Steven Gallinger, James R Woodgett, BMC Cancer (2005) Jun 27;5(1):66.
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/15982419

The links between Axin and carcinogenesis

Sima Salahshor and James R. Woodgett, Journal of Clinical Pathology (2005) 58:225-236
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/15735151?dopt=Abstract

Intraductal papillary mucinous neoplasm of pancreas in a patient with attenuated familial adenomatous polyposis

Runjan Chetty, Sima Salahshor, Bharati Bapat, Terri Berk, Marina Croitoru, Steven Gallinger, Journal of Clinical Pathology (2005) 58:97-101
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/15623495

CDH1 mutations are present in both ductal and lobular breast cancer, but promote allelic variants show no detectable breast cancer risk

Lei H, Sjöberg-Margolin S, Sima Salahshor, Barbaro Werelius, Jandakova E, Hemminki K, Annika Lindblom, Ivor Vorechovsky, International Journal of Cancer (2002) Mar 10;98(2):199-204.
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/11857408

Microsatellite instability and hMlH1, hMSH2 protein expression in familial and sporadic colorectal cancer

Sima Salahshor, Konrad Koelble, Carlos Rubio, Annika Lindblom, Laboratory Investigation (2001) 81: 535-541.
Journal Paper http://www.ncbi.nlm.nih.gov/pubmed/10496341

Current Teaching

  • Present 2010

    LMP1006H- Cellular Imaging in Pathobiology

    University of Toronto, Faculty of Medicine, Toronto, Canada
    Course Leader: Dr. Sima Salahshor

    This course explores the powerful intersection of Physics, Biological science, and Imaging technologies. Different types of microscopes and imaging technologies and their use in biological sciences including dissecting, compound, scanning and transmission electron microscopes, positron emission tomography, single photon emission computed tomography, nuclear magnetic resonance imaging, ultrasound, optical imaging, sterology and 3D imaging, phase contrast, fluorescence and optical microscopy and their use in diagnostic pathology, live cell and whole animal imaging techniques, cytogenetics, and imaging in forensic science will be discussed. This course will focus on the theory, application and implementation of different imaging techniques, and more importantly on application of biological experimentation relevant to modern biological research or clinical biochemical studies and the common real-life research goal in industry, hospitals and research laboratories. Students will be evalulated based on: (1) 10% Participation in Lectures and Laboratory Sessions (2) 25% Midterm Test (3) 35% Written Grant Proposal (4) 30% Oral Presentation. For more information please visit LMP Graduate Course web pages.

  • Present 2011

    LMP1503H- Signal Transduction Pathways in Normal and Diseased Tissue

    University of Toronto, Department of Laboratory of Medicine and Pathobiology, Toronto, Canada
    Course Leader: Dr. Clifford Lingwood

    Signal transduction mechanisms will be described and illustrated by defects in specific human disease states (course summary). For more information please go to University of Toronto, LMP's web pages.

  • 2001 1998

    Clinical Genetics

    Karolinska Institute, Stockholm, Sweden
    Course Leader: Dr. Magnus Nordenskjöld

    This course is designed for Medical Students. "Human Molecular Genetics" written by T. Strachan and A.P. Read is used as the main teaching material and clinical genetics is discussed in the context of specific syndromes, disorders or diseases.